Juliana Cassol Spanemberg

Juliana Cassol Spanemberg

Dentistry, Universidad Fernando Pessoa Canarias, Las Palmas de Gran Canaria, Spain
orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2018 in Medicina Oral Patología Oral y Cirugia Bucal
Verified
Journal Article
Open access
JSJuliana Cassol Spanemberg
Juliana Cassol Spanemberg
ABA Blanco-Carrion
A Blanco-Carrion
MRMe Rodriguez-De Rivera-Campillo
Me Rodriguez-De Rivera-Campillo
AEA Estrugo-Devesa
A Estrugo-Devesa
EJE Jane-Salas
E Jane-Salas
José López-LópezJosé López-López
José López-López
Lichen planus (LP) is a chronic autoimmune disease that affects the oral mucosa as well as the skin, genital mucosa and other sites. to evaluate the correlation between oral, genital and cutaneous lichen planus, in a sample of LP patients. This descriptive study reviewed 274 clinical histories of patients, who all presented histological confirmation of lichen planus verified by a pathologist, attending research centers in Barcelona. A total of 40 LP patients (14.59%) presented genital lesions. Of 131 patients with cutaneous LP (47.8%), the most commonly affected zones were the body's flexor surfaces, representing 60.1% of cases. 24% of patients (n=55) related the start of the lesions with previous stress events. Of the 131 subjects with cutaneous lesions, 19% (n=25) also presented oral lichen planus (OLP). Of the total sample, 53.6% (n=147) of patients presented oral lesions. The systemic diseases most commonly associated with this patient sample were psychological problems such as stress, anxiety and depression (48%), hypertension (27%), gastric problems (12%), and diabetes (9.7%). A family history of lichen planus was found in only 2 cases (0,72%) out of the total of 274. Any patient with OLP should undergo a thorough history and examination to investigate potential extraoral manifestations. The fact that 37 patients with OLP in this patient series were identified with simultaneous involvement at more than one site highlights the need for thorough evaluation and multidisciplinary approaches to this disease.

19 March 2024 in Current Oncology Reports
Verified
Journal Article
Closed access
PDF file
Susell Parra-RojasSusell Parra-Rojas
Susell Parra-Rojas
Rocío Trinidad Velázquez-CayónRocío Trinidad Velázquez-Cayón
Rocío Trinidad Velázquez-Cayón
ABAcorán Borges-Gil
Acorán Borges-Gil
JMJuan Luis Mejías-Torrus
Juan Luis Mejías-Torrus
JSJuliana Cassol Spanemberg
Juliana Cassol Spanemberg

27 September 2024 in Cosmetics
Verified
Journal Article
Open access
PDF file
RFRafael Zago Sa Fortes
Rafael Zago Sa Fortes
JSJuliana Cassol Spanemberg
Juliana Cassol Spanemberg
KCKaren Cherubini
Karen Cherubini
Fernanda Gonçalves SalumFernanda Gonçalves Salum
Fernanda Gonçalves Salum
Objective: The aim of this study was to systematically review the safety and effectiveness of the injectable biostimulators dermal fillers calcium hydroxyapatite (CaHA) and polycaprolactone (PCL) in facial esthetic procedures. Materials and Methods: Comprehensive electronic searches were executed across six academic databases. The primary outcome focused on safety by examining studies that reported the incidence of adverse events (AEs). The secondary outcome gauged the satisfaction of the patients and injectors by validated esthetic scales. To evaluate biases, the Joanna Briggs Institute Checklist tools were employed. Results: We included a total of 79 studies. In the quantitative assessment of the CaHA, out of 5032 injected patients, 21.8% manifested early AEs, 0.85% experienced delayed reactions, and 0.27% had severe complications. Within the PCL group, consisting of 1119 patients, 83.3% exhibited early AEs, 5.6% had delayed reactions, and none had serious complications. Regarding esthetic satisfaction outcome, both products presented favorable results, but a limited number of studies assessed these data. In the studies evaluated qualitatively, a broad array of AEs were cataloged. Conclusions: The occurrence of serious AEs associated with CaHA and PCL fillers is relatively low. Both CaHA and PCL fillers exhibit favorable safety profiles, with most AEs being transient in nature.

22 January 2025 in Biomedicines
Verified
Journal Article
Open access
PDF file
Susell Parra-RojasSusell Parra-Rojas
Susell Parra-Rojas
Rocío Trinidad Velázquez-CayónRocío Trinidad Velázquez-Cayón
Rocío Trinidad Velázquez-Cayón
MCMaria Elena Ciortan-Pop
Maria Elena Ciortan-Pop
MMManoela Domingues Martins
Manoela Domingues Martins
JSJuliana Cassol Spanemberg
Juliana Cassol Spanemberg
Background/Objectives: Oral mucositis (OM) is the most common acute complication among cancer patients. It initially manifests as an inflammatory process, beginning with erythema and edema of the oral mucosa, progressing to erosive lesions, and ultimately leading to highly painful ulcers. This systematic review seeks to evaluate the efficacy of preventive PBM protocols in mitigating chemotherapy-induced OM. Methods: The PRISMA guidelines were followed. The search was conducted in August 2024 in the following databases: Pubmed/Medline, Scopus, WoS, Cochrane, SciELO, BDTD, and BVS/IBECS. Only randomized clinical trials that utilized preventive photobiomodulation protocols in chemotherapy patients were included. All studies involving patients previously treated with radiation therapy were excluded. The Joanna Briggs Institute tool was employed for risk of bias analysis. Results: The total sample size consisted of 828 patients aged between 1 and 84 years. There was no predisposition based on gender or age. When the patients were evaluated under preventive protocols, some cases of mucositis manifested in a total of 339 cases. Of the total number of patients in the 13 selected studies (n = 828), 40.94% developed oral mucositis over the course of chemotherapy cycles. Comparing the experimental and control groups, 211 patients who did not receive preventive laser treatment developed oral mucositis; in contrast, only 128 in the experimental group did. Eighty-five percent of the studies exhibited a low risk of bias. Conclusions: Preventively applied photobiomodulation proves effective in minimizing or even preventing the manifestation of oral mucositis and reducing the severity of lesions that arise during oncological treatment. Registration PROSPERO (CRD42023465329).

16 October 2024 in Biomedicines
Verified
Journal Article
Open access
PDF file
Susell Parra-RojasSusell Parra-Rojas
Susell Parra-Rojas
JSJuliana Cassol Spanemberg
Juliana Cassol Spanemberg
NRNerea del Mar Díaz Robayna
Nerea del Mar Díaz Robayna
MPMariela Peralta-Mamani
Mariela Peralta-Mamani
Rocío Trinidad Velázquez-CayónRocío Trinidad Velázquez-Cayón
Rocío Trinidad Velázquez-Cayón
Background: We report on the cost-effectiveness of photobiomodulation (PBM) for the prevention and treatment of oral mucositis (OM) derived from the cytotoxic effects of antineoplastic therapy. Methods: This review followed the PRISMA 2020 guidelines. A search was conducted in PubMed, Scopus, Web of Science, Embase, and OpenGrey. Articles published before 23 July 2024, were included. Randomized controlled trials (RCTs) that included patients with head and neck cancer undergoing chemotherapy and/or radiotherapy and a placebo group compared to an intervention group (PBM) were selected. The risk of bias was evaluated using the Joanna Briggs Institute tools. The certainty of the evidence was assessed using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach and was rated as moderate. Results: A total of 3 RCTs and 229 patients were included. PBM may represent an additional cost in the short term, but the incremental expenses derived from the cytotoxic effects of antineoplastic therapy are greater in the medium–long term. The intervention group (PBM) showed a lower incidence of severe OM compared to the control group (placebo). Conclusions: PBM is a cost-effective long-term treatment, effective in preventing severe OM and improving the quality of life of cancer patients. More RCTs following the same standardized protocols are needed (registration CDR42024498825).

1 January 2012 in Revista Odonto Ciência
Verified
Journal Article
Open access
PDF file
JSJuliana Cassol Spanemberg
Juliana Cassol Spanemberg
ADAnna Paula Dias
Anna Paula Dias
BBBernardo Ottoni Braga Barreiro
Bernardo Ottoni Braga Barreiro
KCKaren Cherubini
Karen Cherubini
MFMaria Antonia Z. de Figueiredo
Maria Antonia Z. de Figueiredo
Fernanda Gonçalves SalumFernanda Gonçalves Salum
Fernanda Gonçalves Salum